Applicant: Jun-ichi Nezu et al.

Serial No.: 09/521,195 Filed: March 7, 20

Page

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely correct typographical errors and insert sequence identifiers in the specification. Furthermore, the amendments replace the original Sequence Listing with an amended version wherein the amino acid sequence in claim 28 is included. No new matter has been added.

Attached hereto is a marked-up version of the changes made to claim 28 by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted

cket No.: 06501-057001 / C2-

906DP1PCT-US

Date: // /00. / 200

Janis K. Fraser, Ph.D., J.D.

Reg. No. 34,819

Fish & Richardson P.C. 225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20342697.doc

Applicant: Jun-ichi Nezu et al.

Serial No.: 09/521,195 Filed: March 7, 2000

Page

1 "

"Version With Markings to Show Changes Made"

Attorney's L

RECEIVED

cket No.: 06501-057001 / C2-

906DP1PCT-US

JAN 2 2 2002

In the claims:

Claim 28 has been amended as follows:

Xaa12 is Gly, Ser, Thr, or Ala.

**TECH CENTER 1600/2900** 

28. (Amended) The polypeptide of claim 1, wherein the polypeptide comprises the sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Gly-Arg-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12 (SEQ ID NO:33), wherein

Xaa1 is Leu, Ile, Val, Met, Ser, Thr, Ala, or Gly;
Xaa2 is Leu, Ile, Val, Met, Phe, Ser, Ala, or Gly;
Xaa3 is any amino acid;
Xaa4 is Leu, Ile, Val, Met, Ser, Ala [Xaa5 is Asp or Glu];
Xaa5 is Asp or Glu;
Xaa6 is any amino acid;
Xaa7 is Leu, Ile, Val, Met, Phe, Tyr, Trp, or Ala;
Xaa8 is Arg or Lys;
Xaa9 is any amino acid;
Xaa10 is any amino acid;
Xaa11 is any amino acid; and